# Skeptic's Evaluation: Aβ-Tau Synergy Hypotheses
---
## Hypothesis 1: Prion-Like Cross-Seeding via Toxic Oligomer Interfaces
### Strongest Weakness
**Unresolved structural basis for the claimed interface.** The hypothesis asserts that Aβ*56 oligomers "expose cryptic β-strand domains" that interact specifically with tau's R2/R3 repeat domain, but no study has characterized the actual structural interaction. Cross-seeding in vitro typically requires direct mixing of recombinantly aggregated proteins under non-physiological concentrations—this does not establish that membrane-associated oligomers in the human brain template tau conformation with meaningful efficiency.
### Counter-Evidence
- **Reproducibility concerns with Aβ*56**: The original Aβ*56 characterization (Lesné et al., 2006) has not been robustly replicated by independent groups. Many studies now focus on Aβ*56 as an artifact or minor species in vivo. The reliance on this specific oligomer is a fragile foundation (see PMID 23254930 for review of replication issues).
- **Tau propagation can occur independently**: In mouse models where tau is genetically deleted or silenced, Aβ deposition still occurs normally—but critically, *tau pathology can still spread in the absence of Aβ in models using human tau* (Busche et al., 2019, PMID 30643256). This suggests tau seeding has autonomous capacity.
### Pointed Question
**If the cryptic β-strand domains are truly "cryptic" (not exposed in mature fibrils but only in oligomers), how do you propose to specifically detect and quantify these transient interfacial surfaces in vivo in human brain?** Without a method to verify the presence and abundance of these interfaces during life, the mechanism remains inferential.
### Confidence: **Weak → Moderate (conditional)**
The *concept* of cross-seeding is mechanistically plausible and in vitro evidence supports the possibility. However, reliance on Aβ*56 (reproducibility concerns) and absence of structural characterization of the proposed interface substantially weaken the specific claim. Confidence would increase substantially if validated structural data on the Aβ-tau interface became available, or if Aβ*56 were replaced with a better-evidenced oligomeric species.
---
## Hypothesis 2: Kinase-Phosphatase Set-Point Disruption
### Strongest Weakness
**The causal direction is unproven.** The hypothesis proposes that Aβ oligomers "permanently" raise GSK3β activity, creating a feed-forward loop. However, all cited evidence is *correlative*—post-mortem brains showing reduced PP2A and elevated GSK3β are end-stage observations that cannot establish causation. GSK3β elevation could be a *consequence* of neurodegeneration, inflammation, or upstream metabolic dysfunction rather than a driver of the Aβ-tau